Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO.
Raimondi A, Lonardi S, Murgioni S, Cardellino GG, Tamberi S, Strippoli A, Palermo F, De Manzoni G, Bencivenga M, Bittoni A, Chiodoni C, Lorenzini D, Todoerti K, Manca P, Sangaletti S, Prisciandaro M, Randon G, Nichetti F, Bergamo F, Brich S, Belfiore A, Bertolotti A, Stetco D, Guidi A, Torelli T, Vingiani A, Joshi RP, Khoshdeli M, Beaubier N, Stumpe MC, Nappo F, Leone AG, Pircher CC, Leoncini G, Sabella G, Farulla LA, Alessi A, Morano F, Martinetti A, Niger M, Fassan M, Di Maio M, Kaneva K, Milione M, Nimeiri H, Sposito C, Agnelli L, Mazzaferro V, Di Bartolomeo M, Pietrantonio F. Raimondi A, et al. Among authors: murgioni s. Ann Oncol. 2024 Dec 3:S0923-7534(24)04953-6. doi: 10.1016/j.annonc.2024.11.016. Online ahead of print. Ann Oncol. 2024. PMID: 39637944 Free article.
KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration.
Moretto R, Rossini D, Murgioni S, Ciracì P, Nasca V, Germani MM, Calegari MA, Vetere G, Intini R, Taravella A, Studiale V, Boccaccio C, Passardi A, Tamburini E, Zaniboni A, Salvatore L, Pietrantonio F, Lonardi S, Masi G, Cremolini C. Moretto R, et al. Among authors: murgioni s. JCO Precis Oncol. 2024 Nov;8:e2400329. doi: 10.1200/PO.24.00329. Epub 2024 Nov 7. JCO Precis Oncol. 2024. PMID: 39509668
Short- and Long-Term Outcomes in Elderly Patients with Resectable Esophageal Cancer: Upfront Esophagectomy Compared to Surgery after Neoadjuvant Treatments.
Moletta L, Pierobon ES, Capovilla G, Zuin IS, Carrillo Lizarazo JL, Nezi G, Lonardi S, Murgioni S, Galuppo S, Zanchettin G, Salvador R, Provenzano L, Valmasoni M. Moletta L, et al. Among authors: murgioni s. J Clin Med. 2024 Jul 22;13(14):4271. doi: 10.3390/jcm13144271. J Clin Med. 2024. PMID: 39064311 Free PMC article.
Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to action.
Fornaro L, Lonardi S, Catanese S, Nappo F, Pietrantonio F, Pellino A, Angerilli V, Signorini F, Salani F, Murgioni S, Neculaescu IA, Bruno R, Vivaldi C, Ricagno G, Masi G, Bergamo F, Ugolini C, Fassan M. Fornaro L, et al. Among authors: murgioni s. Gastric Cancer. 2023 Nov;26(6):958-968. doi: 10.1007/s10120-023-01411-3. Epub 2023 Jun 29. Gastric Cancer. 2023. PMID: 37382783
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer.
Antoniotti C, Boccaccino A, Seitz R, Giordano M, Catteau A, Rossini D, Pietrantonio F, Salvatore L, McGregor K, Bergamo F, Conca V, Leonetti S, Morano F, Papiani G, Tamburini E, Bensi M, Murgioni S, Ross DT, Passardi A, Boquet I, Nielsen TJ, Galon J, Varga MG, Schweitzer BL, Cremolini C. Antoniotti C, et al. Among authors: murgioni s. Clin Cancer Res. 2023 Jun 13;29(12):2291-2298. doi: 10.1158/1078-0432.CCR-22-3878. Clin Cancer Res. 2023. PMID: 37022350 Clinical Trial.
Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study.
Nappo F, Fornaro L, Pompella L, Catanese S, Lavacchi D, Spallanzani A, Cappetta A, Puzzoni M, Murgioni S, Barsotti G, Tirino G, Pellino A, Vivaldi C, Strippoli A, Aprile G, Di Donato S, Mazza E, Prisciandaro M, Antonuzzo L, Zagonel V, Cascinu S, De Vita F, Lonardi S. Nappo F, et al. Among authors: murgioni s. J Cancer Res Clin Oncol. 2023 Aug;149(9):6601-6611. doi: 10.1007/s00432-023-04636-y. Epub 2023 Feb 16. J Cancer Res Clin Oncol. 2023. PMID: 36795195 Free PMC article.
Simultaneous care in oncology: Assessment of benefit in relation to symptoms, sex, and age in 753 patients.
Galiano A, Schiavon S, Nardi M, Guglieri I, Pambuku A, Martino R, Bolshinsky M, Murgioni S, Intini R, Soldà C, Marino D, Daniel F, De Toni C, Pittarello C, Chiusole B, Prete AA, Bimbatti D, Nappo F, Caccese M, Bergamo F, Brunello A, Lonardi S, Zagonel V. Galiano A, et al. Among authors: murgioni s. Front Oncol. 2022 Oct 14;12:989713. doi: 10.3389/fonc.2022.989713. eCollection 2022. Front Oncol. 2022. PMID: 36313660 Free PMC article.
ctDNA as promising tool for the assessment of minimal residual disease (MRD) and the need of an adjuvant treatment in gastroesophageal adenocarcinoma.
Piva VM, De Grandis MC, Zuin IS, Angerilli V, Nappo F, Alfieri R, Ahcene Djaballah S, Murgioni S, Bergamo F, Fassan M, Valmasoni M, Lonardi S. Piva VM, et al. Among authors: murgioni s. Updates Surg. 2023 Feb;75(2):305-312. doi: 10.1007/s13304-022-01379-2. Epub 2022 Oct 22. Updates Surg. 2023. PMID: 36272058 Review.
34 results